Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$71.53
-0.1%
$66.79
$51.06
$82.22
$8.49B0.882.01 million shs1.14 million shs
JAN stock logo
JAN
JAN
$25.19
+2.2%
$25.46
$22.76
$28.52
$6.63B2.161.14 million shs2.57 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.10%+7.50%+7.81%+6.17%+32.83%
JAN stock logo
JAN
JAN
+2.35%-6.44%-4.83%+240.81%+240.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$71.53
-0.1%
$66.79
$51.06
$82.22
$8.49B0.882.01 million shs1.14 million shs
JAN stock logo
JAN
JAN
$25.19
+2.2%
$25.46
$22.76
$28.52
$6.63B2.161.14 million shs2.57 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.10%+7.50%+7.81%+6.17%+32.83%
JAN stock logo
JAN
JAN
+2.35%-6.44%-4.83%+240.81%+240.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.54
Moderate Buy$81.6014.08% Upside
JAN stock logo
JAN
JAN
2.83
Moderate Buy$28.4512.98% Upside

Current Analyst Ratings Breakdown

Latest BSFA, JAN, HALO, and PHE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy$90.00
6/3/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
6/1/2026
JAN stock logo
JAN
JAN
Boost Price TargetOverweight$27.00 ➝ $31.00
5/27/2026
JAN stock logo
JAN
JAN
Boost Price TargetOutperform$28.00 ➝ $30.00
5/27/2026
JAN stock logo
JAN
JAN
Boost Price TargetSector Outperform$28.00 ➝ $30.00
5/13/2026
JAN stock logo
JAN
JAN
Boost Price TargetOverweight$26.00 ➝ $30.00
5/12/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
UpgradeHold (C)Buy (B-)
5/12/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Lower Price TargetOverweight$96.00 ➝ $93.00
5/8/2026
JAN stock logo
JAN
JAN
Boost Price TargetOutperform$27.00 ➝ $30.00
4/29/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Boost Price TargetBuy$90.00 ➝ $95.00
4/15/2026
JAN stock logo
JAN
JAN
UpgradeHold
(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B6.07$4.77 per share15.01$0.42 per share170.31
JAN stock logo
JAN
JAN
$822.58M8.06N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$2.7825.737.790.3023.13%187.91%21.92%8/4/2026 (Estimated)
JAN stock logo
JAN
JAN
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BSFA, JAN, HALO, and PHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.54$1.60+$0.06$1.22$358.60 million$376.71 million
5/5/2026Q1 2026
JAN stock logo
JAN
JAN
$0.23$0.23N/A$0.23$157.96 million$200.35 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
JAN stock logo
JAN
JAN
$0.642.54%N/AN/AN/A

Latest BSFA, JAN, HALO, and PHE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2026
JAN stock logo
JAN
JAN
quarterly$0.15992.26%6/12/20266/12/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
8.81
2.76
2.33
JAN stock logo
JAN
JAN
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
JAN stock logo
JAN
JAN
6.27%

Insider Ownership

CompanyInsider Ownership
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
JAN stock logo
JAN
JAN
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390118.61 million115.65 millionOptionable
JAN stock logo
JAN
JAN
N/A263.14 millionN/AN/A

Recent News About These Companies

Wall Street Zen Downgrades JAN (NYSE:JAN) to Sell
Insider Sale: President & CEO of $MSTR Sells 16,303 Shares
Insider Purchase: Chairman and CEO of $BH Buys 535 Shares
STEALTHGAS ($GASS) Releases Q1 2026 Earnings, Stock Rises
Celestica shares slide as momentum cools after record run-up
Insider Purchase: CEO and President of $NHI Buys 1,500 Shares
JAN Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$71.53 -0.07 (-0.10%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$71.86 +0.33 (+0.47%)
As of 06/5/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

JAN stock logo

JAN NYSE:JAN

$25.19 +0.54 (+2.17%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$25.12 -0.07 (-0.28%)
As of 06/5/2026 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025. All of our communities are owned and operated under RIDEA structures. Services provided by our operators under a RIDEA structure are primarily paid for directly by the residents, rather than governmental reimbursement programs, which provides us with greater visibility into operating cash flow from our communities. We will be externally managed by Healthpeak Investment Management, LLC, an indirect subsidiary of Healthpeak, which will be our largest stockholder following the completion of this offering and the formation transactions. Healthpeak is an S&P 500 REIT that invests in and manages real estate focused on healthcare discovery and delivery in the United States. Although our Manager was recently formed, Healthpeak has been a public company and an active investor in healthcare real estate for over 40 years. Healthpeak has an extensive network for sourcing and managing senior housing investments that it has established over its long operating history, and we will benefit from this network through our Manager. Our initial portfolio reflects our commitment to delivering sustainable growth through differentiated senior housing solutions and strategic collaborations with high quality operators. We intend to focus exclusively on the senior housing sector because we believe that favorable demographic trends will enable us to create long-term value for our stockholders. We intend to grow our initial portfolio by drawing on our Manager’s origination and sourcing capabilities and established relationships to execute on attractive investment opportunities in the senior housing sector. Of the 34 senior housing communities in our initial portfolio, we describe 15 of these communities, comprising an aggregate of 7,067 units as of December 31, 2025, as “life plan communities.” Life plan communities are a form of senior housing that offer a full continuum of care, including independent living, assisted living, memory care, and skilled nursing, in large-scale communities. Life plan communities differ from other housing and care options for seniors because they typically operate under an entrance fee model, which requires a one-time entrance fee in addition to monthly resident fees, and offer integrated housing, activities, services, and healthcare benefits on a single campus. Life plan communities are designed for individuals and couples seeking an active lifestyle where they can avoid moving a second or third time as they age, and most entrance fee contracts include some level of discounted rates on future healthcare. Compared to traditional rental senior housing, life plan communities offer resident-driven decision making, lifestyle choice, peace of mind from continuum of care, and larger units, with most of our independent living units averaging approximately 1,100 square feet. Residents typically enter our life plan communities in good health in their late 70s or early 80s and stay for eight to ten years — substantially longer than in traditional rental senior housing — supporting stable occupancy and predictable cash flows. The large size of our life plan community campuses, spanning 48 acres of land on average and consisting of approximately 471 units on average as of December 31, 2025, allows us to offer more substantial indoor and outdoor amenities to provide a highly active social life for seniors and create a differentiated senior housing product with high barriers to entry. Due to sizeable land needs, high development costs, financing challenges and pre-leasing requirements, new supply of life plan communities is very low, thereby enabling favorable supply and demand fundamentals for incumbents. We believe life plan communities exhibit consistently resilient occupancy, positioning them as a business with embedded operating leverage and growth visibility, which in turn can provide strong risk-adjusted returns. The other 19 senior housing communities in our initial portfolio, comprising an aggregate of 3,355 units as of December 31, 2025, are primarily independent living, with certain communities offering assisted living, memory care, and/or skilled nursing. These communities are often amenitized, apartment-like buildings with private residences ranging from studios to large apartments. We were formed in December 2025. Our principal executive office is located in Denver, CO.